Jul 02, 2020 (Profound via COMTEX) -- Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain. The underlying condition of this type of obstruction is the development of fat deposits lining the vessel walls, which is known as atherosclerosis. According to the World Health Organization (WHO), stroke accounts for around 17 million deaths annually. As per the Centers for Disease Control and Prevention (CDC), stroke leads to 1 out of every 20 deaths costing around USD 34 billion each year in the U.S. Higher rates of mortality associated with strokes highlight an impending need for innovative drugs and diagnostic devices.
The key strategies adopted by leading industry players incldues new product launches and collaborations. For instance, in April 2016, the novel TransCarotid Artery Revascularization (TCAR) procedure launched by Silk Road Medical, Inc, received FDA approval. This minimally invasive technique is designed to access the common carotid artery. Moreover, in March, 2015, WATCHMAN, a closure device designed to prevent stroke in patients with atrial fibrillation received FDA approval.
Download Sample - https://www.novaoneadvisor.com/report/sample/2330
The ischemic stroke is segmented on the basis of diagnosis, drug class, surgery and end-users.
On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others.
On the basis of the drug class, the market is segmented into tissue plasminogen activator, anticoagulant, antiplatelet, antihypertensive, and others
On the basis of the surgery, the market is segmented into carotid endarterectomy, angioplasty, and endovascular mechanical thrombectomy
On the basis of the end-user, the market is segmented into hospitals amp; clinics, medical institutes, research organization, and others.
The emergence of new and cost-effective medication options for the treatment of ischemic stroke could open up new opportunities to the new players in the global ischemic stroke market. Additionally, emerging markets, such as India and China, could also open new opportunities to new players.
Some of key the players in the Americas ischemic stroke market are Abbott Laboratories (U.S.), Medtronic plc (U.S.), Boston Scientific Corporation (U.S.), Cordis Corporation (U.S.), Koninklijke Philips N.V. (Netherland), GE Healthcare (U.S.), Stryker Corporation (U.S.), Genentech, Inc. (U.S.), Merck amp; Co., Inc. (U.S.), Bayer AG (Germany), Boehringer Ingelheim (Germany), Sanofi (France), Covidien plc (Ireland), Philips Healthcare (U.S.), Johnson amp; Johnson (U.S.), Penumbra, Inc. (U.S.), GE Healthcare (U.S.), Siemens Healthcare (U.S.), Hitachi, Ltd (Japan), Biogen (U.S.), Daiichi Sankyo (U.S.), Pfizer Inc. (U.S.), and others
Download Full Report - https://www.novaoneadvisor.com/report/checkout/2330
PDF File Dispatch Time - 24 Hours. We Will also support Word, PPT, Excel Files Dispatch
Nova One Advisor
Mailing Address: 237 West 35th Street,Suite 605,New York, NY 10001, USA
Any Assistance, Email ndash; email@example.com
Is there a problem with this press release? Contact the source provider Comtex at firstname.lastname@example.org. You can also contact MarketWatch Customer Service via our Customer Center.